New derivatives of 3,5-substituted-1,4,2-dioxazoles: Synthesis and activity against Entamoeba histolytica

被引:31
作者
Bhat, Abdul R. [1 ]
Athar, Fareeda. [1 ]
Azam, Amir [1 ]
机构
[1] Jamia Millia Islamia, Dept Chem, New Delhi 110025, India
关键词
Dioxazole; Antiamoebic activity; Entamoeba histolytica; MTT assay; BIOLOGICAL EVALUATION; AGENTS; METRONIDAZOLE; REDUCTASE;
D O I
10.1016/j.ejmech.2008.02.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Dioxazole derivatives (1-33) were synthesized in two steps via their corresponding oximes (I-III). All the compounds were characterized using various spectroscopic techniques. A comparative study of in vitro antiamoebic activity of these heterocyclic compounds, viz. 3-o-chloro (1-11), 3-m-chloro (12-22) and 3-p-chloro (23-33) dioxazoles having same substituents at 5-position of dioxazole ring, was performed against HM1:IMSS strain of Entamoeba histolytica. The results showed a regular pattern in the activity and out of 33 compounds assayed 15 compounds showed better antiamoebic activity than metronidazole with IC50 values in the range 0.41-1.73 mu M and 1.80 mu M. Dioxazoles having o-chloro, m-chloro, p-chloro, dichloro and pyridine substituents at 5-position were more active than the standard drug metronidazole. The toxicity studies against human kidney epithelial cell line showed that all the compounds were non-toxic. 3,5-Bis-[2-chlorophenyl]-1,4,2-dioxazole (10) was most active and least toxic among all the compounds. (C) 2008 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:926 / 936
页数:11
相关论文
共 30 条
[1]  
ADAGU IS, 2002, CHEMOTHERAPY, V49, P103
[2]  
[Anonymous], 1997, Wkly Epidemiol Rec, V72, P97
[3]  
[Anonymous], 2007, CURR BIOACT COMPD, DOI DOI 10.2174/157340707780809590
[4]   IMMUNOPHARMACOLOGICAL PROFILE OF HWA-486, A NOVEL ISOXAZOL DERIVATIVE .2. INVIVO IMMUNOMODULATING EFFECTS DIFFER FROM THOSE OF CYCLOPHOSPHAMIDE, PREDNISOLONE, OR CYCLOSPORINE-A [J].
BARTLETT, RR .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1986, 8 (02) :199-204
[5]  
Brandt H, 1970, Hum Pathol, V1, P351
[6]   Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [muraglitazar BMS-298585], a novel peroxisome proliferator-activated receptor α/γ dual agonist with efficacious glucose and lipid-lowering activities [J].
Devasthale, PV ;
Chen, S ;
Jeon, Y ;
Qu, FC ;
Shao, CN ;
Wang, W ;
Zhang, H ;
Cap, M ;
Farrelly, D ;
Golla, R ;
Grover, G ;
Harrity, T ;
Ma, ZP ;
Moore, L ;
Ren, J ;
Seethala, R ;
Cheng, L ;
Sleph, P ;
Sun, W ;
Tieman, A ;
Wetterau, JR ;
Doweyko, A ;
Chandrasena, G ;
Chang, SY ;
Humphreys, WG ;
Sasseville, VG ;
Biller, SA ;
Ryono, DE ;
Selan, F ;
Hariharan, N ;
Cheng, PTW .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) :2248-2250
[7]   NEW MEDIUM FOR AXENIC CULTIVATION OF ENTAMOEBA-HISTOLYTICA AND OTHER ENTAMOEBA [J].
DIAMOND, LS ;
HARLOW, DR ;
CUNNICK, CC .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1978, 72 (04) :431-432
[8]  
Fromtling R. A., 1986, DRUG TODAY, V20, P235
[9]  
GIFFIN FD, 1982, ANTIMICROB AGENTS CH, V22, P342
[10]   Isoxazole-type derivatives related to combretastatin A-4, synthesis and biological evaluation [J].
Kaffy, Julia ;
Pontikis, Renee ;
Carrez, Daniele ;
Croisy, Alain ;
Monneret, Claude ;
Florent, Jean-Claude .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (12) :4067-4077